Log In
BCIQ
Print this Print this
 

CRLX301

  Manage Alerts
Collapse Summary General Information
Company Cerulean Pharma Inc.
DescriptionNanoparticle conjugated to docetaxel
Molecular Target Tubulin
Mechanism of ActionTubulin inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today